Carlos Campos-Marques

  • Tau
  • Alzheimer's disease
  • Down Syndrome
  • antisense oligonucleotides

Carlos Campos-Marques holds a BSc degree in Biochemistry (School of Sciences, University of Minho) and a MSc degree in Health Sciences (School of Medicine, University of Minho). As undergraduate and master student, he worked in Dr Ioannis Sotiropoulos’ lab, focusing on the “multifaceted” role of Tau protein on neuroplasticity, neuropathology as well as therapy on different disease states. Thus, he has worked on different projects such as monitoring the neuroplastic role of Tau on chronic pain, as well as clarifying the role of Tau protein on mitochondria structure and function. During his Master studies, he focused on a new therapeutic strategy – antisense oligonucleotides (ASOs) – for brain disorders related to Tau pathology such as Alzheimer’s disease (AD) and Down Syndrome (DS). Thus, through an on-going collaboration with RNA Therapeutics Institute, MA, USA, he was involved in the design and cell-line testing of ASOs against Tau malfunction as previous studies have suggested that reduction of Tau levels could be beneficial against brain malfunction in different brain pathologies that exhibited accumulation of Tau. Currently he is a Researcher fellowship at ICVS/3B’s Associated Laboratory (University of Minho, Braga). Carlos has presented his research results in national and international conferences (e.g., EBPS meeting 2019, SPN 2021, Symposium on Oligonucleotide Technology and Therapeutics 2021).